Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The immunopeptidomic landscape of ovarian carcinomas.

Schuster H, Peper JK, Bösmüller HC, Röhle K, Backert L, Bilich T, Ney B, Löffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee HG, Stevanović S, Staebler A, Wagner P.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951. doi: 10.1073/pnas.1707658114. Epub 2017 Nov 1.

2.

Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells.

Wang DH, Wu XH, Qian SM, Yao HR.

Med Oncol. 2015 Apr;32(4):116. doi: 10.1007/s12032-015-0561-7. Epub 2015 Mar 17. Erratum in: Med Oncol. 2015 Jul;32(7):189.

PMID:
25779534
3.

Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.

Mariya T, Hirohashi Y, Torigoe T, Asano T, Kuroda T, Yasuda K, Mizuuchi M, Sonoda T, Saito T, Sato N.

Cancer Immunol Res. 2014 Dec;2(12):1220-9. doi: 10.1158/2326-6066.CIR-14-0101. Epub 2014 Oct 16.

4.

Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer.

O'Shannessy DJ, Jackson SM, Twine NC, Hoffman BE, Dezso Z, Agoulnik SI, Somers EB.

Int J Mol Sci. 2013 Jul 1;14(7):13687-703. doi: 10.3390/ijms140713687.

5.

MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.

Gubbels JA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, Petrie S, Migneault M, Rancourt C, Connor JP, Patankar MS.

Mol Cancer. 2010 Jan 20;9:11. doi: 10.1186/1476-4598-9-11.

6.

ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.

Sinnathamby G, Zerfass J, Hafner J, Block P, Nickens Z, Hobeika A, Secord AA, Lyerly HK, Morse MA, Philip R.

Clin Exp Immunol. 2011 Mar;163(3):324-32. doi: 10.1111/j.1365-2249.2010.04298.x. Epub 2010 Dec 22.

7.

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.

Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS.

Mol Cancer. 2006 Oct 26;5(1):50.

8.

Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.

Bandiera E, Zanotti L, Fabricio AS, Bucca E, Squarcina E, Romani C, Tassi R, Bignotti E, Todeschini P, Tognon G, Romagnolo C, Gion M, Sartori E, Maggino T, Pecorelli S, Ravaggi A.

Clin Chem Lab Med. 2013 Sep;51(9):1815-24. doi: 10.1515/cclm-2013-0151.

PMID:
24013103
9.

High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma.

Cheng WF, Huang CY, Chang MC, Hu YH, Chiang YC, Chen YL, Hsieh CY, Chen CA.

Br J Cancer. 2009 Apr 7;100(7):1144-53. doi: 10.1038/sj.bjc.6604964. Epub 2009 Mar 17.

10.

[Tumor Marker CA125: biochemical and molecular properties].

Bouanène H, Miled A.

Bull Cancer. 2009 May;96(5):597-601. doi: 10.1684/bdc.2009.0859. Epub 2009 May 12. Review. French.

11.

Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.

Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV.

Cancer Immunol Immunother. 2012 Aug;61(8):1243-53. doi: 10.1007/s00262-012-1201-0. Epub 2012 Jan 19.

PMID:
22258792
12.

Clinicopathologic significance of HLA-G and HLA-E molecules in Tunisian patients with ovarian carcinoma.

Babay W, Ben Yahia H, Boujelbene N, Zidi N, Laaribi AB, Kacem D, Ben Ghorbel R, Boudabous A, Ouzari HI, Rizzo R, Rebmann V, Mrad K, Zidi I.

Hum Immunol. 2018 Jun;79(6):463-470. doi: 10.1016/j.humimm.2018.02.012. Epub 2018 Mar 2.

PMID:
29499226
13.

Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1.

Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, Shrikant PA, Gnjatic S, Old LJ, Odunsi K.

Cancer Immunol Immunother. 2008 Aug;57(8):1185-95. doi: 10.1007/s00262-008-0450-4. Epub 2008 Feb 6.

PMID:
18253733
14.

Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.

Garcia-Soto AE, Schreiber T, Strbo N, Ganjei-Azar P, Miao F, Koru-Sengul T, Simpkins F, Nieves-Neira W, Lucci J 3rd, Podack ER.

Gynecol Oncol. 2017 Jun;145(3):413-419. doi: 10.1016/j.ygyno.2017.03.512. Epub 2017 Apr 6.

PMID:
28392126
15.

Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells.

Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, Stockert E, Driscoll D, Lele S, Old LJ, Odunsi K.

Clin Cancer Res. 2006 Jan 15;12(2):398-404. Erratum in: Clin Cancer Res. 2006 Mar 1;12(5):1656. Gjnatic, Sacha [corrected to Gnjatic, Sacha].

16.

Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.

Coelho R, Marcos-Silva L, Ricardo S, Ponte F, Costa A, Lopes JM, David L.

Expert Rev Anticancer Ther. 2018 Feb;18(2):177-186. doi: 10.1080/14737140.2018.1418326. Epub 2017 Dec 21. Review.

PMID:
29241375
17.

An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response.

Pinciroli P, Alberti C, Sensi M, Canevari S, Tomassetti A.

BMC Genomics. 2013 Jul 26;14:508. doi: 10.1186/1471-2164-14-508.

18.

Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.

Garg M, Chaurasiya D, Rana R, Jagadish N, Kanojia D, Dudha N, Kamran N, Salhan S, Bhatnagar A, Suri S, Gupta A, Suri A.

Clin Cancer Res. 2007 Mar 1;13(5):1421-8.

19.

Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.

Xu N, Zhang Z, Zhu J, Xu L, Li Y, Duan L, Mao Y, Li H.

Int J Exp Pathol. 2016 Apr;97(2):150-8. doi: 10.1111/iep.12174. Epub 2016 Apr 29.

20.

Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.

Peng DX, Luo M, Qiu LW, He YL, Wang XF.

Oncol Rep. 2012 Apr;27(4):1238-44. doi: 10.3892/or.2012.1625. Epub 2012 Jan 11.

Supplemental Content

Support Center